NOVATAE RISK GROUP NAMES BRIAN VOORHEES MANAGING DIRECTOR, PERSONAL LINES
Voorhees is a seasoned insurance executive with extensive experience across underwriting, business development, product management and operational leadership. Most recently, he directed day-to-day operations for Applied Home National Underwriters where he led underwriting strategy, growth initiatives, broker relationships and a nationwide team supporting the high-net-worth market. Prior to that, Voorhees served as vice president of business development at NatGen Premier, managing a
"Brian's depth of experience and leadership across underwriting, operations and distribution make him an outstanding addition to our organization," said
"Throughout my career, I've been passionate about building strong teams, developing disciplined underwriting strategies and delivering meaningful solutions for brokers and clients," said
About Novatae Risk Group
Novatae Risk Group (Novatae) is a full-service wholesale insurance brokerage, underwriting manager and Lloyd's Coverholder, providing brokers and their clients with specialty insurance products and services for complex and hard-to-place risks across a broad spectrum of property, casualty and specialty lines. Novatae, the wholesale division of World Insurance Associates LLC, serves more than 6,000 clients from 37 offices across the
About World Insurance Associates LLC
World Insurance Associates (World) is a nationally ranked financial services organization headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/novatae-risk-group-names-brian-voorhees-managing-director-personal-lines-302764611.html
SOURCE Novatae Risk Group
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
- Bitcoin BTC Price Prediction 2027: Is $100K Realistic or Could BTC Reach $150K And How It Helps MemeToro Presale
- ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share